Activity of preclinical and phase I clinical trial of a novel androgen receptor antagonist GT0918 in metastatic breast cancer

PURPOSE: To evaluate GT0918, a 2nd-generation AR antagonist, for its AR down-regulation activity among breast cancer patients. METHODS: The effect of GT0918 on AR protein expression was evaluated in AR expression breast cancer cells and in breast cancer xenograft model. A 3 + 3 phase I dose-escalati...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Huiping, Song, Guohong, Zhou, Qiaoxia, Ran, Ran, Jiang, Hanfang, Zhang, Ruyan, Liu, Yaxin, Zhang, Jiayang, Meng, Luping, Ma, Liandong, Sun, Ye, Wang, Meiyu, Zhou, Qingqing, Yan, Honghua, Zhou, Qianxiang, Dong, Xunwei, Tong, Youzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505310/
https://www.ncbi.nlm.nih.gov/pubmed/34392453
http://dx.doi.org/10.1007/s10549-021-06345-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505310/
https://www.ncbi.nlm.nih.gov/pubmed/34392453
http://dx.doi.org/10.1007/s10549-021-06345-x

Ejemplares similares